In Alzheimer’s disease (AD) the brain is damaged by a great many neuroinflammatory processes and therefore the authors suggested that therapy aimed to protect neurons and to reduce neuroinflammation may prove quite useful.

Palmitoylethanolamide (PEA) has attracted their attention because of its anti-inflammatory and neuroprotective properties in a great number of Alzheimer models.

Neuroprotective effects of PEA in Alzheimer braincells

In a sophisticated experiment the scientists evaluated these protective and anti-inflammatory roles of PEA against the damage done to the brain by the toxic amyloid-β protein.

PEA Alzheimer disease

The pathological and damaging effects in the brain could be counteracted by the pretreatment with PEA. Other negative effects on neurotransmitter level also were counteracted by PEA.

Palmitoylethanolamide is used as a painkiller and anti-inflammatory natural compound, but PEA can do much more. It can protect the nerves in Alzheimer brains.


Advice for use of PEA

We prefer treatment either with the Italian PEA tablets, based on PEA-um or PEA-m, or by administrating the Dutch PEA capsules containing PEA-opt. Dutch capsules do not contain any chemical fillers and contain 400 mg 100% pure PEA in vegetarian capsules.

For pain relief and for inhibiting inflammation, most patients choose:

  • PEA capsules produced in the Netherlands by Russell
  • PEA tablets produced in Italy by Epitech

Only for these Dutch and the Italian formulations long term safety and efficacy data gathered under the supervision of MDs are available. And only for these formulations (PEA-um, PEA-m and PEA-opt) there are currently data available proving that after intake PEA levels in the body significantly rise. Such data do not exist for me-too PEA formulations.


  1. Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice.

Tomasini MC, Borelli AC, Beggiato S, Ferraro L, Cassano T, Tanganelli S, Antonelli T.

J Alzheimers Dis. 2015;46(2):407-21. doi: 10.3233/JAD-143039.